论文部分内容阅读
目的：探讨肺癌中ｃｅｒｂＢ２癌基因和ｎｍ２３转移抑制基因的表达与临床病理的关系。方法：应用免疫组化技术（ＳＰ法），对６２例肺癌标本的ｃｅｒｂＢ２和ｎｍ２３基因及其产物的表达进行检测。结果：ｃｅｒｂＢ２癌基因在肺癌中的阳性表达率为６１２９％，与肺癌患者的性别、年龄、肿块大小、组织学类型和分化程度等因素无关，与患者的淋巴结转移呈正相关（Ｐ＜００５）。ｎｍ２３转移抑制基因在肺癌中增强表达率为７４１９％，与肺癌患者的年龄，肿块大小无关，与患者的性别和肿瘤的分化程度有显著性差异（Ｐ＜００５）。ｎｍ２３增强表达与淋巴结转移呈负相关（Ｐ＜００５）。与肺癌的组织学类型有极显著差异（χ２＝８７８５３，Ｐ＜００１），鳞癌组增强高于腺癌组。结论：ｃｅｒｂＢ２和ｎｍ２３在肺癌中均有较高表达，ｃｅｒｂＢ２基因表达反映肿瘤旺盛，易淋巴结转移；而ｎｍ２３转移抑制基因高表达与淋巴结转多呈负相关，是肺癌预后的良好标志。
Objective: To investigate the relationship between cerbB2 oncogene and nm23 metastasis suppressor gene expression and clinicopathology in lung cancer. METHODS: Immunohistochemical technique (SP method) was used to detect the expression of cerbB2 and nm23 genes and their products in 62 lung cancer specimens. RESULTS: The positive expression rate of cerbB2 oncogene in lung cancer was 6129%. It was not related to factors such as sex, age, tumor size, histological type and differentiation of lung cancer patients. It was positively correlated with lymph node metastasis of patients. (P<005). The enhanced expression rate of nm23 metastasis suppressor gene in lung cancer was 7419%, which was not related to the age and size of tumor in patients with lung cancer. It was significantly different from the gender and tumor differentiation of patients (P<005). There was a negative correlation between nm23-enhanced expression and lymph node metastasis (P<005). There was a significant difference between the histological types of lung cancer (χ2=87853, P<001) and the squamous cell carcinoma group was significantly more advanced than the adenocarcinoma group. Conclusion: CerbB2 and nm23 are all highly expressed in lung cancer. The cerbB2 gene expression reflects the tumor’s exuberance and lymph node metastasis. The high expression of nm23 metastasis suppressor gene is negatively correlated with lymph node metastasis. Good sign of prognosis.